JPRN-jRCTs051220109招募中Unknown
Evaluation of treatment response for immune checkpoint inhibitors in non-small cell lung cancer patients using [18F]F-AraG PET/CT
akamoto Yuji0 个研究点目标入组 60 人开始时间: 2022年10月26日最近更新:
适应症
试验速览
- 阶段
- Unknown
- 状态
- 招募中
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 85age old（—）
- 性别
- All
入选标准
- •1) Confirmed non-small cell lung cancer by pathology.
- •2) Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 or 2.
- •3) Patients without history of immune checkpoint inhibitors approved in Japan, but clinically applicable and planned to be prescribed.
- •4) Patients who performed FDG-PET/CT
排除标准
- •1) Pregnant, possibly pregnant, or breastfeeding women.
- •2) Very poor physical condition.
- •3) Outstandingly difficult in communication.
研究者
相似试验
已完成
不适用
Prospective study on evaluation of immune response after SARS-CoV-2 vaccinatioHealthy SubjectJPRN-UMIN000045492Shionogi & Co., Ltd.143
招募中
不适用
Study protocol for the HARMONY studyKCT0005173Korea Institute of Oriental Medicine200
已完成
不适用
Investigation of post-treatment after immune checkpoint inhibitor treatment for advanced or recurrent non-small cell lung cancerlung cancerJPRN-UMIN000033594Japanese Red Cross Medical Center37
已完成
不适用
Prospective study on evaluation of immunological response after SARS-CoV-2 vaccinatioCOVID-19JPRN-UMIN000045097Shionogi & Co., Ltd.205
进行中（未招募）
1 期
Evaluation of immunological response following a revaccination with a non-conjugated pneumococcal vaccine boosted or not by a conjugated pneumococcal vaccine in splenectomised patients (SPLENEVAC-2)Asplenic patients at risk for invasive pneumococcal diseasesMedDRA version: 20.0Level: PTClassification code 10041642Term: SplenectomySystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2018-003068-29-FRASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)56